FMP
Marker Therapeutics, Inc.
MRKR
NASDAQ
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
1.03 USD
0 (0%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
466.79k
1.24M
9M
3.31M
6.59T
10.49T
16.7T
26.59T
42.33T
67.39T
Revenue %
-
166.01
625.17
-63.23
199.06M
59.19
59.19
59.19
59.19
Ebitda
-27.63M
-36.32M
-19.79M
-11.79M
-11.12T
-10.49T
-16.7T
-26.59T
-42.33T
-67.39T
Ebitda %
-5.92k
-2.92k
-219.79
-356.14
-168.69
-100
-100
-100
-100
Ebit
-28.71M
-39.48M
-23.47M
-14.58M
-4.53M
-8.39T
-13.36T
-21.27T
-33.86T
-53.91T
Ebit %
-6.15k
-3.18k
-260.66
-440.37
-0
-80
-80
-80
-80
Depreciation
1.08M
3.16M
3.68M
2.79M
-11.12T
4.72T
7.52T
11.97T
19.06T
30.34T
Depreciation %
230.44
254.7
40.87
84.23
-168.69
45.02
45.02
45.02
45.02
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
